Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: September 27, 2022

Details for Patent: 9,732,062

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,732,062 protect, and when does it expire?

Patent 9,732,062 protects IDHIFA and is included in one NDA.

This patent has fifty-three patent family members in thirty-eight countries.

Summary for Patent: 9,732,062
Title:Therapeutically active compounds and their methods of use
Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Inventor(s): Cianchetta; Giovanni (Waltham, MA), DeLaBarre; Byron (Arlington, MA), Popovici-Muller; Janeta (Waltham, MA), Salituro; Francesco G. (Marlborough, MA), Saunders; Jeffrey O. (Lincoln, MA), Travins; Jeremy (Southborough, MA), Yan; Shunqi (Irvine, CA), Guo; Tao (Dayton, NJ), Zhang; Li (Shanghai, CN)
Assignee: Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/735,467
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,732,062

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,732,062

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090411 See Plans and Pricing
Australia 2013207289 See Plans and Pricing
Australia 2017265096 See Plans and Pricing
Brazil 112014016805 See Plans and Pricing
Canada 2860623 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.